Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma.
about
Immunobiology of hepatocarcinogenesis: Ways to go or almost there?Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysisNovel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and developmentTargeted therapy for hepatocellular carcinoma: novel agents on the horizonCurrent systemic treatment of hepatocellular carcinoma: A review of the literatureENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo.Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression.Arecoline induces HA22T/VGH hepatoma cells to undergo anoikis - involvement of STAT3 and RhoA activationILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progressionSTAT3 activation in monocytes accelerates liver cancer progression.Withaferin A inhibits activation of signal transducer and activator of transcription 3 in human breast cancer cells.Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target.Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling.Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3Prognostic value of protein inhibitor of activated STAT3 in breast cancer patients receiving hormone therapy.Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in hepatocellular carcinoma.Nuclear HDAC6 inhibits invasion by suppressing NF-κB/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer.TLR4 signaling promotes a COX-2/PGE2/STAT3 positive feedback loop in hepatocellular carcinoma (HCC) cells.The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas.The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.Human growth hormone and human prolactin function as autocrine/paracrine promoters of progression of hepatocellular carcinomaExpression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma.Targeted therapy via oral administration of attenuated Salmonella expression plasmid-vectored Stat3-shRNA cures orthotopically transplanted mouse HCC.YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.Liver regeneration microenvironment of hepatocellular carcinoma for prevention and therapyDiagnosis and treatment of hepatocellular carcinoma: An update.The influence of TLR4 agonist lipopolysaccharides on hepatocellular carcinoma cells and the feasibility of its application in treating liver cancer.A polysaccharide from mushroom Huaier retards human hepatocellular carcinoma growth, angiogenesis, and metastasis in nude mice.Increased adiponectin associated with poor survival in hepatocellular carcinoma.Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice.Secretion of interleukin-6 by bone marrow mesenchymal stem cells promotes metastasis in hepatocellular carcinoma.Stattic Enhances Radiosensitivity and Reduces Radio-Induced Migration and Invasion in HCC Cell Lines through an Apoptosis Pathway.Decreased total MKP-1 protein levels predict poor prognosis in breast cancer.p19(ARF) /p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma.Clinicopathological significance and prognostic role of p-STAT3 in patients with hepatocellular carcinoma.
P2860
Q26738293-54DDB489-05EA-4CF4-88D0-90BA9CFA93F9Q26784351-1DD8A097-955B-42BA-8F02-7FFA29E27FDEQ26851211-1EEBD312-AF34-4811-B9EA-56F8F98A1368Q27002288-FABF4F35-3D31-4A6F-BAE1-6253CB679C0AQ27026036-E1460A5A-B880-44DE-A810-1F6BF86EB110Q33354649-3172922E-4EC7-4961-9F98-451989672ED0Q33740488-85A00FA2-53C0-43C2-A7EF-C14FDFE805A2Q33955193-2C2AF6C5-8DD1-4637-9A12-7D5972B9478EQ33977419-ED95B393-6DEE-4C4F-86AA-082469E8FE19Q34089708-F8EEECE7-4F7D-4466-9E08-3702CB0128AAQ34253370-B379B3EE-F381-42CE-9C34-BDF66376CB5BQ34940989-B22B78A6-D6FA-4FBD-815D-D7B2A6A0D0D4Q35225695-73FBC01A-DE01-47F3-9C26-A10B398C57FCQ35404280-9EDFFA83-7ADB-416D-96D7-D88FEAE64A75Q35894524-142FBFDA-9C6F-4E0C-8543-093DAB0258A0Q36230775-614C0C23-E966-4565-B1C2-F9E155BCE939Q36557560-F4AF287E-E9E0-4D3A-8F46-CA1C75FB5F23Q36710952-4A2A70B2-8E49-47EF-A5CA-F67063EAAACEQ37020840-CCE2C51C-D14B-43A6-AEFB-AC39F8380ED8Q37244392-6CB1B661-BE89-4035-A667-57E6B1394C5BQ37301860-78FFF994-040A-4260-8E90-943BDFB54A8CQ37345331-E0E75D49-C806-4C1B-9517-A71231C43B5DQ37478042-02BA1C11-41CE-4093-BAF2-023CECF5C2CFQ37493227-1A62C797-5A1B-4DD3-BE77-E6A50A43D680Q37702183-90E4D534-F067-4E7D-90F1-7151A0AEE28BQ38408866-9BF39945-F7A9-42A9-AAB2-A9C49EA5C8C2Q38837307-39EE19BB-B4D1-4DD0-AB81-83C7C0C8A1F9Q38930303-E53E7DDB-2F4D-491F-A799-C9DD48D8D220Q39077663-F014BCC9-A817-418E-B205-D039326932D5Q39318012-1480A1CD-8051-466C-BF46-8D4FCD6C83E7Q41488328-C3C051D3-53AE-41D3-85F0-06198AEC8020Q47096604-F2C899F5-E6AE-4F20-B745-109BB4A32C47Q53171569-FFDC4022-D226-43A0-BDF5-CD1DE7C61BEEQ53257577-F1227D17-35E2-465B-8468-0DD55FCD71C7Q55692333-409E72D3-DC92-4624-A24D-8CC3EFAE5FA8
P2860
Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Altered p-STAT3 (tyr705) expre ...... y in hepatocellular carcinoma.
@ast
Altered p-STAT3 (tyr705) expre ...... y in hepatocellular carcinoma.
@en
type
label
Altered p-STAT3 (tyr705) expre ...... y in hepatocellular carcinoma.
@ast
Altered p-STAT3 (tyr705) expre ...... y in hepatocellular carcinoma.
@en
prefLabel
Altered p-STAT3 (tyr705) expre ...... y in hepatocellular carcinoma.
@ast
Altered p-STAT3 (tyr705) expre ...... y in hepatocellular carcinoma.
@en
P2093
P2860
P356
P1476
Altered p-STAT3 (tyr705) expre ...... y in hepatocellular carcinoma.
@en
P2093
Chee-Yin Chai
Chih-Fung Wu
King-Teh Lee
Maw-Chang Sheen
Sheau-Fang Yang
Shen-Nien Wang
Shih-Chang Chunag
Yao-Tsung Yeh
P2860
P304
P356
10.1136/JCP.2006.036970
P407
P577
2006-08-10T00:00:00Z